Trial Profile
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Faricimab (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms TENAYA
- Sponsors Roche
- 01 May 2023 Results of subgroup analysis (n=133) assessing 1-year efficacy, durability, and safety of faricimab versus aflibercept in patients with neovascular age-related macular degeneration (nAMD) enrolled in the Japan subgroup published in the Japanese Journal of Ophthalmology
- 26 Apr 2023 According to Genentech Media Release, post-hoc pooled analysis data from TENAYA and LUCERNE (wet AMD) and YOSEMITE and RHINE (DME) studies were shared in three presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from April 23-27 in New Orleans, LA.
- 25 Apr 2023 Results of pooled post-hoc analysis from TENAYA and LUCERNE studies presented in a Genentech media release.